Beacon Financial Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Beacon Financial Advisory’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$304K	Buy	581 +19	+3%	+$9.7K	0.06%	335
2026 Q2	$279K	Sell	562 -7	-1%	-$3.1K	0.06%	347
2026 Q1	$254K	Buy	569 +27	+5%	+$12.6K	0.06%	345
2025 Q4	$246K	Buy	+542	New	+$234K	0.06%	332
2025 Q2	–	Sell	-533	Closed	-$258K	–	370
2025 Q1	$258K	Buy	+533	New	+$248K	0.08%	268
2024 Q4	–	Sell	-446	Closed	-$207K	–	313
2024 Q3	$207K	Buy	446 +12	+3%	+$5.76K	0.07%	276
2024 Q2	$203K	Buy	+434	New	+$188K	0.08%	272
2024 Q1	–	Sell	-512	Closed	-$208K	–	278
2023 Q4	$208K	Buy	+512	New	+$189K	0.1%	234

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Beacon Financial Advisory's VRTX Position: Q3 2026 in Review

Beacon Financial Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 3.4% in Q3 2026, buying an estimated $9.7K and bringing the position to 581 shares worth $304K. The position accounts for 0.06% of the portfolio, ranked #335.

Beacon Financial Advisory first reported a position in VRTX in Q4 2023 and has held it in 8 quarters since. 700 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Beacon Financial Advisory held 581 shares of Vertex Pharmaceuticals worth $304K as of Q3 2026.
Beacon Financial Advisory bought 19 Vertex Pharmaceuticals shares in Q3 2026, an estimated $9.7K.
Vertex Pharmaceuticals made up 0.06% of Beacon Financial Advisory's portfolio in Q3 2026, its #335 holding.
Beacon Financial Advisory first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
700 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Beacon Financial Advisory's 13F filing for Q3 2026, filed 16 Oct 2026.